Tuesday 29 March | |
Impax Asset Management Group PLC | AGM |
Tekmar Group PLC | AGM |
Wednesday 30 March | |
Brunner Investment Trust PLC | AGM |
Mediazest PLC | AGM |
Micro Focus International PLC | AGM |
Parsley Box Group PLC | GM re equity raise |
Power Metal Resources PLC | GM re carried forward losses |
Power Metal Resources PLC | AGM |
Thursday 31 March | |
Pressure Technologies PLC | AGM |
Red Rock Resources PLC | AGM |
Aukett Swanke Group PLC | AGM |
Various Eateries PLC | AGM |
Toople PLC | AGM |
BiVictriX Therapeutics PLC | AGM |
CloudCoCo Group PLC | AGM |
Friday 1 April | |
Gfinity PLC | GM re fundraising |
River & Mercantile Group PLC | AGM |
Monday 4 April | |
Poolbeg Pharma PLC | AGM |
Copyright 2022 Alliance News Limited. All Rights Reserved. |
IN BRIEF: Poolbeg Pharma shares rise as first human trial begins
Poolbeg Pharma PLC - London-based pharmaceutical company - Receives approval to commence its Lipopolysaccharide human clinical trial for POLB 011, a drug that aims to treat severe influenza. The trial will formally start on Friday. It will assess POLB 011 in damping the immune response to lipopolysaccharide, which acts as a surrogate for the hyperinflammatory response associated with severe influenza. Initial results are expected in the final quarter of 2022. Poolbeg says at that point it intends to "rapidly" monetise by out-licensing and/or partnering with pharmaceutical and biotechnology companies for the drug's further development.
Read more